Geriatric Medicine Department, Geriatric Oncology Clinic, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Internal Medicine Service, Hospital General Dr. Manuel Gea González, Mexico City, Mexico.
Curr Oncol Rep. 2024 Sep;26(9):991-1020. doi: 10.1007/s11912-024-01558-x. Epub 2024 Jun 12.
This review aims to summarize the current evidence regarding the prognostic role of frailty in older patients diagnosed with cancer and to explore the evidence regarding its prognostic implications in cancer survivors.
Frailty has been consistently associated with mortality/overall survival, postoperative complications, short- and long-term postoperative mortality, length of stay, among other adverse health-related outcomes in several oncological contexts. The possible association between frailty and treatment toxicity has been less explored, however most studies suggest frailty is a predictor of treatment induced toxicity. In addition, in cancer survivors, frailty is a risk factor for cardiovascular disease, incident type 2 diabetes mellitus, mortality, altered cognitive performance and increased symptom severity. Due to its usefulness in establishing prognosis and informing treatment decision making, it is expected that frailty screening and assessment will continue to gain popularity as part of the pretreatment evaluation of older patients with cancer.
本文旨在总结目前有关虚弱在老年癌症患者中的预后作用的证据，并探讨其在癌症幸存者中的预后意义。
在多种肿瘤学背景下，虚弱与死亡率/总生存率、术后并发症、短期和长期术后死亡率、住院时间等不良健康相关结局均存在关联。然而，虚弱与治疗毒性之间的可能关联尚未得到充分探索，大多数研究表明虚弱是治疗引起的毒性的预测因子。此外，在癌症幸存者中，虚弱是心血管疾病、2 型糖尿病、死亡率、认知功能改变和症状严重程度增加的危险因素。由于其在确定预后和为治疗决策提供信息方面的有用性，预计虚弱筛查和评估将作为老年癌症患者治疗前评估的一部分继续受到欢迎。
